Market research
CYAD.BR Celyad Oncology SA
BR EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 19M
- P/E ratio
- 13.0
- Analyst target
- 0.5
- Dividend yield
- Not available
- Beta
- 1.21
Profile
Company facts
- Exchange
- BR
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- BE0974260896
- Market cap
- 19M
- P/E ratio
- 13.0
- Analyst target
- 0.5
- Dividend yield
- Not available
- Beta
- 1.21
About
About Celyad Oncology SA
Celyad Oncology SA, a biotechnology company, focuses on unlocking the potential of its intellectual property. Its portfolio comprises multiple foundational US patents focused on TCR-deficient T cell compositions, and it broadly covers allogeneic CAR T cell therapies. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CYAD.BR discussion.
5 years, 5 months ago
Celyad Oncology SA is currently in a long term downtrend where the price is trading 34.5% below its 200 day moving average.
From a valuation standpoint, the stock is 73.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 17093.3.
Celyad Oncology SA's total revenue sank by 16.7% to $5K since the same quarter in the previous year.
Its net income has dropped by 31.0% to $-17M since the same quarter in the previous year.
Finally, its free cash flow grew by 2.0% to $-7M since the same quarter in the previous year.
Based on the above factors, Celyad Oncology SA gets an overall score of 2/5.